WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

NCT03297359 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

92

Enrollment

OTHER

Sponsor class

Stopped Low recruitment

Conditions

Cancer
Venous Thromboembolism
Obesity

Interventions

BIOLOGICAL: Dalteparin

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]